profit from every $100 of sales.
$0$100
Acurx Pharmaceuticals
$1.03-0.96% today
-81.5% in 1 year
1-year low $0.951-year high $6.63
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Acurx Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$7.97 million of profit last year.
SalesProfit
Acurx Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Acurx Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Acurx Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -12 | -15 | -14 | -8 | |
| -12 | -15 | -14 | -8 | |
| -12 | -15 | -14 | -8 | |
| -22.40 | -23.00 | -17.45 | -5.32 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9 | 8 | 4 | 8 |
| Cash | 9 | 7 | 4 | 8 |
| Total debt | – | – | – | – |
| Total liabilities | 2 | 3 | 3 | 2 |
| 7 | 5 | 1 | 5 | |
| 1 | 1 | 1 | 1 | |
| -130.6% | -246.8% | -1,813.8% | -121.3% | |
| -165.3% | -312.4% | -2,292.7% | -151.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -10 | -10 | -7 | |
| – | – | – | – | |
| -8 | -10 | -10 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 0 | |
| 3 | 4 | 3 | 2 |
Valuation
- –
- –
- –
- 0.6×
- –
- –
- 1,284.6×
- -120,448.2%
- -141.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -153.1%
- -604.9%
- -215.6%
- -103.6%
- -153.1%
- –
Growth
- –
- –
- −65,271.3%
- –
- +30.9%
Financial health
- -1,285.1×
- 0.00
- 0.0%
- –
- 3.18
- 3.18
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 888
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.62 | -0.59 | −5.1% |
| Mar 13, 2026 | -0.31 | -1.01 | +69.3% |
| Nov 12, 2025 | -1.23 | -1.61 | +23.6% |
| Aug 11, 2025 | -1.89 | -2.00 | +5.5% |
| May 12, 2025 | -2.20 | -0.15 | −1,366.7% |
| Mar 17, 2025 | -0.16 | -0.18 | +11.1% |
| Nov 12, 2024 | -0.17 | -0.23 | +26.1% |
| Aug 9, 2024 | -0.26 | -0.28 | +7.1% |
News
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstatSeeking Alpha · Aug 14, 2026The newest story we have is from Aug 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
77Pass
Philip Fisher
23No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
25No pass
Questions about Acurx Pharmaceuticals
Is Acurx Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Acurx Pharmaceuticals AI analysis
What does Acurx Pharmaceuticals do?
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. It is in Biotechnology.
Does Acurx Pharmaceuticals pay a dividend?
No. Acurx Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $1,040 to shareholders by buying back its own shares.
Is Acurx Pharmaceuticals stock halal?
No. Acurx Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 134% of its market value, at or above the 33% limit. How we check
How has Acurx Pharmaceuticals stock done over the past year?
Down 81.5% over the past twelve months, to $1.03. It traded between $0.95 and $6.63 and is 84.5% below its high.
Who are Acurx Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Acurx Pharmaceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.